Table 1.
ALL (n = 188) |
VAHL (n = 27) |
MHL (n = 21) |
EqHL (n = 140) |
Pv a | ||
---|---|---|---|---|---|---|
Male/Female | 87/101 | 13/14 | 2/19 | 72/68 | <0.01 | |
Age Mean (SD), y | 63.9 (14.6) | 66.6 (14.4) | 65.9 (12.8) | 63 (14.8) | 0.42 | |
Disease, No. (%) | Malignancy | |||||
Breast cancer | 37 (19.7) | 3 (11) | 17 (81) | 18 (12.9) | <0.01 | |
Lymphoma | 27 (14.4) | 3 (11) | 2 (10) | 22 (15.7) | 0.66 | |
Lung cancer | 25 (13.3) | 7 (26) | 1 (5) | 17 (12.1) | 0.07 | |
Other malignancy | 77 (41) | 12 (44) | 1 (5) | 65 (46.4) | <0.01 | |
Non-malignancy | 23 (12.2) | 2 (7) | 0 (0) | 19 (13.6) | 0.15 | |
Timing of imaging test, No. (%) | ||||||
Pre-treatment | 113 (60.1) | 15 (56) | 13 (62) | 85 (60.7) | 0.87 | |
During treatment | 29 (15.4) | 3 (11) | 8 (38) | 18 (12.9) | <0.01 | |
Post-treatment | 46 (24.4) | 9 (33) | 0 (0) | 37 (26.4) | <0.05 | |
Vaccination, No. (%) | 183 (97.3) | 27 (100) | 16 (76) | 140 (100) | <0.01 |
Categorical variables are reported as frequencies and percentages. Continuous variables are reported as median and interquartile range (IQR). a p-value of the test among the three groups.